JP2019512018A5 - - Google Patents

Download PDF

Info

Publication number
JP2019512018A5
JP2019512018A5 JP2018560436A JP2018560436A JP2019512018A5 JP 2019512018 A5 JP2019512018 A5 JP 2019512018A5 JP 2018560436 A JP2018560436 A JP 2018560436A JP 2018560436 A JP2018560436 A JP 2018560436A JP 2019512018 A5 JP2019512018 A5 JP 2019512018A5
Authority
JP
Japan
Prior art keywords
hom
composition
tissue sample
expression
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018560436A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019512018A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/015775 external-priority patent/WO2017136322A1/en
Publication of JP2019512018A publication Critical patent/JP2019512018A/ja
Publication of JP2019512018A5 publication Critical patent/JP2019512018A5/ja
Priority to JP2022143467A priority Critical patent/JP7635939B2/ja
Priority to JP2024153550A priority patent/JP2024170560A/ja
Pending legal-status Critical Current

Links

JP2018560436A 2016-02-04 2017-01-31 炎症性障害の治療及び診断 Pending JP2019512018A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022143467A JP7635939B2 (ja) 2016-02-04 2022-09-09 炎症性障害の治療及び診断
JP2024153550A JP2024170560A (ja) 2016-02-04 2024-09-06 炎症性障害の治療及び診断

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662291271P 2016-02-04 2016-02-04
US62/291,271 2016-02-04
PCT/US2017/015775 WO2017136322A1 (en) 2016-02-04 2017-01-31 Treatment and diagnosis of inflammatory disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022143467A Division JP7635939B2 (ja) 2016-02-04 2022-09-09 炎症性障害の治療及び診断

Publications (2)

Publication Number Publication Date
JP2019512018A JP2019512018A (ja) 2019-05-09
JP2019512018A5 true JP2019512018A5 (https=) 2020-03-12

Family

ID=59499992

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018560436A Pending JP2019512018A (ja) 2016-02-04 2017-01-31 炎症性障害の治療及び診断
JP2022143467A Active JP7635939B2 (ja) 2016-02-04 2022-09-09 炎症性障害の治療及び診断
JP2024153550A Pending JP2024170560A (ja) 2016-02-04 2024-09-06 炎症性障害の治療及び診断

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022143467A Active JP7635939B2 (ja) 2016-02-04 2022-09-09 炎症性障害の治療及び診断
JP2024153550A Pending JP2024170560A (ja) 2016-02-04 2024-09-06 炎症性障害の治療及び診断

Country Status (13)

Country Link
US (3) US11268095B2 (https=)
EP (1) EP3411479A4 (https=)
JP (3) JP2019512018A (https=)
KR (1) KR20180109985A (https=)
CN (1) CN108779461A (https=)
AU (2) AU2017213744B2 (https=)
CA (1) CA3013898A1 (https=)
CL (3) CL2018002097A1 (https=)
IL (2) IL311968A (https=)
MX (2) MX2018009542A (https=)
MY (2) MY203831A (https=)
SG (2) SG11201806636SA (https=)
WO (1) WO2017136322A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3411479A4 (en) 2016-02-04 2019-09-18 Zhenglun Zhu TREATMENT AND DIAGNOSIS OF INFLAMMATORY DISEASES
JP2022526671A (ja) 2019-04-11 2022-05-25 エンクリアー セラピーズ, インク. 脳脊髄液の改善の方法ならびにそのためのデバイスおよびシステム
CN111528842B (zh) * 2020-05-26 2023-01-03 复嶂环洲生物科技(上海)有限公司 基于生理和行为指标的帕金森病症状定量化评估方法
JP2023543868A (ja) 2020-09-29 2023-10-18 エンクリアー セラピーズ, インク. くも膜下液管理方法およびシステム
CA3225436A1 (en) * 2021-06-23 2022-12-29 Enclear Therapies, Inc. Method of regulating gene expression

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2709309B1 (fr) 1993-08-25 1995-11-10 Centre Nat Rech Scient Compositions cellulaires, préparation et utilisations thérapeutiques.
US5583153A (en) 1994-10-06 1996-12-10 Regents Of The University Of California Use of taxol in the treatment of rheumatoid arthritis
US20030035790A1 (en) 1999-01-15 2003-02-20 Shu-Hsia Chen Combination therapy for the prevention or treatment of cancer, inflammatory disorders or infectious diseases in a subject
EP1222933A1 (en) 2001-01-15 2002-07-17 Academisch Ziekenhuis Leiden h.o.d.n., Leids Universitair Medisch Centrum Generation and/or reduction of new lung tissue in an affected lung, by modulation of the Wnt-pathway
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
JP2006519008A (ja) 2003-02-10 2006-08-24 独立行政法人産業技術総合研究所 哺乳動物細胞の調節
JPWO2005070964A1 (ja) 2004-01-27 2008-01-17 株式会社医学生物学研究所 単球の単離方法
WO2006086345A2 (en) 2005-02-07 2006-08-17 The Trustees Of Columbia University In The City Of New York Methods to treat or prevent hormone-resistant prostate cancer using sirna specific for protocadherin-pc, or other inhibitors of protocadherin-pc expression or activity
WO2007051077A2 (en) 2005-10-28 2007-05-03 The Regents Of The University Of California Methods and compounds for lymphoma cell detection and isolation
WO2007078599A2 (en) 2005-12-16 2007-07-12 The Board Of Trustees Of The Leland Stanford Junior University Functional arrays for high throughput characterization of gene expression regulatory elements
US20070161031A1 (en) 2005-12-16 2007-07-12 The Board Of Trustees Of The Leland Stanford Junior University Functional arrays for high throughput characterization of gene expression regulatory elements
CN107446033B (zh) 2006-02-22 2022-04-01 朱正崙 发育相关疾病的治疗
HUE042736T2 (hu) 2009-07-15 2019-07-29 Zhenglun Zhu Gyulladásos vagy autoimmun rendellenességek kezelésének irányítása HOM-1 kifejezés alkalmazásával
WO2012071513A2 (en) * 2010-11-24 2012-05-31 Hong Gao Expanding hematopoietic stem cells
WO2012170979A1 (en) 2011-06-10 2012-12-13 Zhenglun Zhu Human homeobox gene ventx and macrophage terminal differentiation and activation, compositions and methods thereof
WO2014093773A1 (en) 2012-12-14 2014-06-19 The Brigham And Women's Hospital, Inc. Methods and assays relating to macrophage differentiation
WO2014169086A1 (en) 2013-04-10 2014-10-16 Zhenglun Zhu Homeobox transcription factor ventx regulates differentiation and maturation of human dendritic cells
US9428748B2 (en) * 2013-06-17 2016-08-30 Hong Gao Method of expanding hematopoietic stem cells
CN108243607A (zh) 2015-09-09 2018-07-03 西雅图儿童医院(Dba西雅图儿童研究所) 用于免疫疗法的巨噬细胞的遗传工程
CN108495931A (zh) 2015-11-11 2018-09-04 朱正崙 一种改变巨噬细胞分化和免疫的方法
EP3411479A4 (en) 2016-02-04 2019-09-18 Zhenglun Zhu TREATMENT AND DIAGNOSIS OF INFLAMMATORY DISEASES
WO2018183447A1 (en) 2017-03-28 2018-10-04 Zhenglun Zhu Methods of treating neoplastic diseases

Similar Documents

Publication Publication Date Title
JP2019512018A5 (https=)
Denby et al. MicroRNA-214 antagonism protects against renal fibrosis
Liu et al. LncRNA MALAT1/MiR-145 adjusts IL-1β-induced chondrocytes viability and cartilage matrix degradation by regulating ADAMTS5 in human osteoarthritis
Manoury et al. TIMP-1 is a key factor of fibrogenic response to bleomycin in mouse lung
Zhang et al. MicroRNA-155 contributes to preeclampsia by down-regulating CYR61
US11053314B2 (en) Methods to eliminate cancer stem cells by targeting CD47
Witalison et al. Molecular targeting of protein arginine deiminases to suppress colitis and prevent colon cancer
ES2724549T3 (es) ARN pequeños derivados de RNY como biomarcadores para trastornos relacionados con la aterosclerosis
Ni et al. CircSLC7A2 protects against osteoarthritis through inhibition of the miR‐4498/TIMP3 axis
Tsolou et al. ‘Stemness’ and ‘senescence’related escape pathways are dose dependent in lung cancer cells surviving post irradiation
WO2021231887A1 (en) Compositions and methods of detection of pre-symptomatic als
Shiba et al. Differential roles of MMP-9 in early and late stages of dystrophic muscles in a mouse model of Duchenne muscular dystrophy
WO2019229259A1 (en) Materials and methods for monitoring the development of resistance of cancers to treatment
CN105987999A (zh) 用于乳腺癌诊断的联合肿瘤标志物及其试剂盒
TW202402790A (zh) 減少呼吸系統感染之方法
Huang et al. ALKBH5-mediated m6A demethylation fuels cutaneous wound re-epithelialization by enhancing PELI2 mRNA stability
Tan et al. Circular RNA XRCC5 aggravates glioma progression by activating CLC3/SGK1 axis via recruiting IGF2BP2
CN114901835B (zh) 包含mir-335的组合物
Yang et al. CircITGA7 regulates malignant phenotypes in bladder cancer cells via targeting miR‐330‐3p/KLF10 axis
US12534729B2 (en) Uses of synthetic lethal partners for treatment of cancer
CN116270710B (zh) circRBM33作为靶点在前列腺癌诊断和治疗中的应用
US9234018B2 (en) Compositions and methods for the treatment of VprBP-related cancers
Xin et al. Upregulation of MiR-29b contributes to mesenchymal stem cell dysfunction in patients with severe pre-eclampsia
EP2670772B1 (en) Antagonists of grasp55 for use as a medicament
Balzanelli et al. The Role of SARS-CoV-2 Spike Protein in Long-term Damage of Tissues and Organs, the Underestimated Role of Retrotransposons and Stem Cells, a Working Hypothesis